 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with a placebo in a recent Phase 3 trial. Results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children and adolescents with Fragile X syndrome FXS were published in the Journal of Neurodevelopmental Disorders, the company said. 